… with the PE in the RE-COVER/RE-COVER II studies. We, … pooled analysis of the RE-COVER/RE-COVER
II studies, which corresponds with 2.9% for patients treated with dabigatran…

… of life (HRQoL) after acute DVT and pulmonary embolism (PE) … The RE‐COVER and
RE‐COVER II studies randomized … of treatment with either dabigatran (150 mg BID) or warfarin …

… in patients with deep vein thrombosis and/or pulmonary embolism (DVT/PE). The objective
… study than those reported in a pooled analysis of the RE-COVER and RE-COVER II …

… (New York Heart Association classes II–IV), and pooled 6-minute walk distance … apixaban
and rivaroxaban, respectively. The RE-COVER II trial confirmed the findings of the RE-COVER …

… pulmonary embolism or if pulmonary embolism could not be ruled out. … dabigatran versus
warfarin for the treatment of acute venous thromboembolism: a pooled analysis from re‐cover …

… phase of parenteral heparin anticoagulation for 7–10 days; two further DOACs, apixaban and
rivaroxaban, were also tested as part of a … with dabigatran or warfarin and pooled analysis. …

… proximal DVT (PDVT) or pulmonary embolism (PE), suggesting a need for different … analysis
is based on the first phase. In the second phase, the safety and effectiveness of dabigatran …

… In the RE-COVER and RE-COVER II studies, dabigatran was administered at a fixed dose
of 150 mg twice daily after a lead-in treatment with parenteral unfractionated heparin, LMWH, …

… disorders (standard of care three [3%] of 90, dabigatran two [1%] of … In the RE-COVER trial,
dabigatran was non-inferior to … deep venous thrombosis and pulmonary embolism in children. …

… Two studies investigated an oral DTI (dabigatran) and eight … RE‐COVER II 2014, only
reported outcome data of VTE, not separate data for PE, so we took data from a pooled analysis …